Avidity Biosciences to Present at the 2020 Wells Fargo Virtual Healthcare Conference

Rhea-AI Summary

Avidity Biosciences, Inc. (Nasdaq: RNA) announced that CEO Sarah Boyce will participate in a fireside chat at the 2020 Wells Fargo Virtual Healthcare Conference on September 10 at 9:00 am PT. The event will be held virtually, with a live webcast available on Avidity's website. A replay of the chat will be archived for 60 days. Avidity is focused on developing Antibody Oligonucleotide Conjugates (AOCs) aimed at treating serious diseases, including myotonic dystrophy type 1 and other muscle conditions.

SAN DIEGO, Sept. 3, 2020 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs^™), today announced that Sarah Boyce, Avidity's President and CEO, will participate in a fireside chat at the 2020 Wells Fargo Virtual Healthcare Conference on Thursday, September 10^th, 2020 at 9:00 am PT. The conference is being held in a virtual format.

A live webcast of the virtual fireside chat will be available on the Company's website at www.aviditybiosciences.com in the Investor Resources section. A replay of the fireside chat will be archived on the site for 60 days.

About Avidity Biosciences

Avidity Biosciences, Inc. is pioneering a new class of oligonucleotide-based therapies called AOCs designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. Avidity utilizes its proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. Avidity's lead

product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1, and its four other muscle programs are focused on the treatment of muscle atrophy, Duchenne muscular dystrophy, facioscapulohumeral muscular dystrophy and Pompe disease. In addition to its muscle franchise, Avidity has research efforts focused on immune and other cell types.  

Contacts:

Company:
Mike MacLean
(858) 401-7900
mikemaclean@aviditybio.com          

Media and Investors:

Amy Conrad
Juniper Point
(858) 366-3243
amy@juniper-point.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/avidity-biosciences-to-present-at-the-2020-wells-fargo-virtual-healthcare-conference-301122501.html

SOURCE Avidity Biosciences, Inc.

FAQ

What is Avidity Biosciences' stock symbol?

Avidity Biosciences trades under the stock symbol 'RNA'.

When will Sarah Boyce speak at the Wells Fargo Virtual Healthcare Conference?

Sarah Boyce will speak on September 10, 2020, at 9:00 am PT.

How can I watch the Avidity Biosciences fireside chat?

The fireside chat will be available via live webcast on Avidity's website.

What is Avidity Biosciences' lead product candidate?

Avidity's lead product candidate is AOC 1001, aimed at treating myotonic dystrophy type 1.

What are Antibody Oligonucleotide Conjugates (AOCs)?

AOCs are a new class of therapies designed to treat diseases by combining monoclonal antibodies with oligonucleotide therapies.